Avivagen Announces Feed Conference Attendance in Bangkok, Thailand April 8 to 10

Avivagen Inc.

Healthcare & Pharmaceutical

Share Tweet

Avivagen Announces Feed Conference Attendance in Bangkok, Thailand April 8 to 10

Ottawa, ON / ACCESSWIRE / Apr 7, 2014 / - Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces that it will be attending important trade shows for the animal feed industries serving Asian markets.

Held in Bangkok, Thailand from April 8 to 10, the events are trade shows and conferences dedicated to specialist ingredients, additives and equipment used in the formulation of livestock, aquaculture and pet feeds. Three events are co-located at the Bangkok International Trade and Exhibition Centre and held every two years.

The co-located events are VICTAM Asia, a leading international exhibition and conference for feed industry technologies, FIAAP - concerning Feed Ingredients & Additives for the Asia Pacific region and GRAPAS - relating to Grain Processing and Storage solutions.

Avivagen's CEO, Cameron Groome, will be available for meetings throughout the conferences, which its organizers characterize as attended by visitors from all over the world: "The senior executives - CEOs, directors, mill and transport managers, nutritionists, veterinarians, feed formulators from feed mills, integrators, co-operatives, large farms, fish farms, hatcheries, petfood processors, etc."

Attendance at this event is important to support moving OxC-beta through the process of commercialization as a novel, safe and effective non-antibiotic feed supplement. The conferences provide Avivagen with the opportunity to meet with current and prospective customers and to address questions about OxC-beta - in relation to published results of its prior studies, trials in process and livestock applications.

OxC-beta will be available via the conferences, as it is approved for sale in the Kingdom of Thailand. International distribution enquiries should be directed to Avivagen, while domestic supply requests can be made to the Thai distributor of OxC-beta, Natural Nutrients Co. Ltd. Avivagen is committed to supporting the commercialization of OxC-beta in Asia, with commercial or trial relationships now disclosed in relation to Thailand, Vietnam and Korea.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Livestock Productivity and Pet Wellness.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. More information can be found at www.avivagen.com.

About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research and study results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

The commercial products of Avivagen are OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM) Chewables.

About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In past studies, OxC-beta has been shown to support health and growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.

About Vivamune(TM) Health Chews - For dogs and cats

Vivamune(TM) Health Chews, containing Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.

About Oximunol(TM) Chewables - For dogs

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States.

Forward Looking Statements

This document includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Unless required by law, Avivagen Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

For more information:
Avivagen Inc.
Cameron Groome
CEO & President
[email protected]

100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

 |Copyright© 2014|
 |Avivagen       |
SOURCE: Avivagen Inc.